Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Documenta Ophthalmologica
Published in: Documenta Ophthalmologica 2/2010

01-04-2010 | Original Research Article

Retinal function in patients treated with tamoxifen

Authors: Sung Eun Song Watanabe, Adriana Berezovsky, Márcia Motono, Paula Yuri Sacai, Josenilson Martins Pereira, Juliana Maria Ferraz Sallum, Luiz Henrique Gebrim, Solange Rios Salomão

Published in: Documenta Ophthalmologica | Issue 2/2010

Login to get access

Abstract

Tamoxifen, an effective treatment of breast cancer, has been shown to cause ocular toxic effects. The purpose of this study was to determine retinal toxicity by full-field and focal electroretinograms (ERGs) in patients treated with tamoxifen. Full-field and focal ERGs were obtained from three groups: Tamoxifen—14 females (47–72 years, mean 58.3 ± 9.1) with normal fundus, treated with tamoxifen from 2 to 37 months; No Treatment—10 females (39–65 years, mean 50.1 ± 8.7) with previous breast cancer diagnosis and before tamoxifen treatment; Control—13 normal female volunteers (41–81 years, mean 52.7 ± 12.1). Peak-to-peak amplitude and b-wave implicit time were measured and statistically analyzed. Mean peak-to-peak amplitudes and implicit time from full-field and focal ERGs were comparable for the three different groups. Low-dosage tamoxifen showed no retinotoxic effect assessed by full-field and focal ERG in this small group of women with breast cancer.
Literature
1.
Gordon NH, Silverman P, Lasheen W, Meinert J, Siminoff LA (2007) Thirty-year follow-up of chemo-hormonal therapy in node-positive breast cancer. Breast Cancer Res Treat 102:301–312CrossRefPubMed
2.
Early Breast Cancer Trialists’ Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 352:930–942CrossRef
3.
Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351:1451–1467CrossRef
4.
Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER, Margolese R, Robidoux A, Shibata H, Terz J, Paterson AHG, Feldman MI, Farrar W, Evans J, Lickley L, Ketner M, Abramson N, Allegra JC, Beazley R, Berry J, Boatman KK, Carmichael D, Cruz AB Jr, Davies R, Deckers P, Desser R, Reese M, Economou S, Elias G, Feldman M, Foster RS, Frazier TG, Glass AG, Jochimsen P, Jubelirer S, Kardinal CG, Keyserlingk JR, Lerner HJ, Levick SN, Mahoney L, Mowry P, Nicola M, Oishi R, Pasquale D, Perrault D, Peters G, Poisson R, Pugh R, Robert N, Spector J, Sponzo R, Sterchi JM, Sutherland CM, Thiessen AR, Thirlwell M, Welling R, Wold H, Wozniak T (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumor. N Engl J Med 320:479–484PubMedCrossRef
5.
Jordan VC (1995) Tamoxifen for breast cancer prevention. Proc Soc Exp Biol Med 208:144–149PubMed
6.
Powles TJ (1997) Efficacy of tamoxifen as treatment of breast cancer. Semin Oncol 24(Suppl 1):SI48–SI54
7.
Meier CR, Jick H (1998) Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 45:608–612CrossRefPubMed
8.
9.
Kaiser-Kupfer MI, Lippman ME (1978) Tamoxifen retinopathy. Cancer Treat Rep 62:315–320PubMed
10.
Kaiser-Kupfer MI, Kupfer C, Rodrigues M (1981) Tamoxifen retinopathy: a clinicopathologic report. Ophthalmology 88:89–93PubMed
11.
McKeown CA, Swartz M, Blom J, Maggiano JM (1981) Tamoxifen retinopathy. Br J Ophthalmol 65:177–179CrossRefPubMed
12.
Beck M, Mills PV (1979) Ocular assessment of patients treated with tamoxifen. Cancer Treat Rep 63:1833–1834PubMed
13.
Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, Petroutsos G (1992) Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. Cancer 69:2961–2964CrossRefPubMed
14.
Bernstein PS, DellaCroce JT (2007) Diagnostic & therapeutic challenges. Tamoxifen toxicity. Retina 27:982–988CrossRefPubMed
15.
Cronin BG, Lekich CK, Bourke RD (2005) Tamoxifen therapy conveys increased risk of developing a macular hole. Int Ophthalmol 26:101–105CrossRefPubMed
16.
Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ (1994) Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. Am J Ophthalmol 117:772–775PubMed
17.
Tang R, Shields J, Schiffman J, Li H, Locher D, Hampton J, Prager T, Pardo G (1997) Retinal changes associated with tamoxifen treatment for breast cancer. Eye 11:295–297PubMed
18.
Noureddin BN, Seoud M, Bashshur Z, Salem Z, Shamseddin A, Khalil A (1999) Ocular toxicity in low-dose tamoxifen: a prospective study. Eye 13:729–733PubMed
19.
Gianni L, Panzini I, Li S, Gelber RD, Collins J, Holmberg SB, Crivellari D, Castiglione-Gertsch M, Goldhirsch A, Coates AS, Ravaioli A, International Breast Cancer Study Group (IBCSG) (2006) Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer 106:505–513CrossRefPubMed
20.
Salomão SR, Watanabe SE, Berezovsky A, Motono M (2007) Multifocal electroretinography, color discrimination and ocular toxicity in tamoxifen use. Curr Eye Res 32:345–352CrossRefPubMed
21.
Beck M, Mills PV (1979) Ocular assessment of patients treated with tamoxifen. Cancer Treat Rep 63:1833–1834PubMed
22.
Longstaff S, Sigurdsson H, O′Keeffe M, Ogston S, Preece P (1989) A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma. Eur J Cancer Clin Oncol 25:1805–1808CrossRefPubMed
23.
Easterbrook M (1988) Ocular effects and safety of antimalarial agents. Am J Med 14:23–29CrossRef
24.
Zrenner E (2006) Drug side effects and toxicology of the visual system. In: Heckenlively JR (ed) Principles and practice of clinical electrophysiology of vision, 2nd edn. Cambridge, London, pp 655–662
25.
Kuchenbecker J, Pump-Schmidt C, Olbricht S, Weise W, Behrens-Baumann W (2001) Electrophysiological studies in breast carcinoma patients with tamoxifen retinopathy. Ophthalmologe 98:81–85CrossRefPubMed
26.
Ritter C, Renner AB, Wachtlin J, Bechrakis NE, Krause L (2008) Tamoxifen retinopathy: a case series of clinical and functional data. Ophthalmologe 105:544–549CrossRefPubMed
27.
Gerner EW (1989) Ocular toxicity of tamoxifen. Ann Ophthalmol 21:420–423PubMed
28.
Bentley CR, Davies G, Aclimandos WA (1992) Tamoxifen retinopathy: a rare but serious complication. BMJ 304:495–496CrossRefPubMed
29.
Berezovsky A, Moraes NS, Nusinowitz S, Salomão SR (2003) Standard full-field electroretinography in healthy preterm infants. Doc Ophthalmol 107:243–249CrossRefPubMed
30.
Engelke M, Tykhonova S, Zorn-Kruppa M, Diehl H (2002) Tamoxifen induces changes in the lipid composition of the retinal pigment epithelium cell line D407. Pharmacol Toxicol 91:13–21CrossRefPubMed
31.
Toimela T, Tähti H, Salminen L (1995) Retinal pigment epithelium cell culture as a model for evaluation of the toxicity of tamoxifen and chloroquine. Ophthalmic Res 27:150–153CrossRefPubMed
32.
Gualino V, Cohen SY, Delyfer MN, Sahel JA, Gaudric A (2005) Optical coherence tomography findings in tamoxifen retinopathy. Am J Ophtahlmol 140:757–758CrossRef
33.
Eisner A, Austin DF, Samples JR (2004) Short wavelength automated perimetry and tamoxifen use. Br J Ophthalmol 88:125–130CrossRefPubMed
Metadata
Title
Retinal function in patients treated with tamoxifen
Authors
Sung Eun Song Watanabe
Adriana Berezovsky
Márcia Motono
Paula Yuri Sacai
Josenilson Martins Pereira
Juliana Maria Ferraz Sallum
Luiz Henrique Gebrim
Solange Rios Salomão
Publication date
01-04-2010
Publisher
Springer-Verlag
Published in
Documenta Ophthalmologica / Issue 2/2010
Print ISSN: 0012-4486
Electronic ISSN: 1573-2622
DOI
https://doi.org/10.1007/s10633-009-9203-8

Other articles of this Issue 2/2010

Documenta Ophthalmologica 2/2010 Go to the issue

Case report

Macular function in tilted disc syndrome

Original Research Article

Pattern electroretinogram optimized for glaucoma screening (PERGLA) and retinal nerve fiber thickness in suspected glaucoma and ocular hypertension

Original research article

A comparison of multifocal ERG and frequency domain OCT changes in patients with abnormalities of the retina

Original research article

Correlation between functional and anatomical assessments by multifocal electroretinography and optical coherence tomography in central serous chorioretinopathy

Original research article

Single doses of all-trans-N-retinylacetamide slow down the ERG amplitude recovery after bleaching in rats

OriginalPaper

Statistical test of VEP waveform equality